Published in Heart Fail Rev on November 01, 2013
The Importance of NLRP3 Inflammasome in Heart Failure. J Card Fail (2015) 0.88
The hemodynamic and nonhemodynamic crosstalk in cardiorenal syndrome type 1. Cardiorenal Med (2014) 0.85
Low eosinophil and low lymphocyte counts and the incidence of 12 cardiovascular diseases: a CALIBER cohort study. Open Heart (2016) 0.78
Acute exercise-induced response of monocyte subtypes in chronic heart and renal failure. Mediators Inflamm (2014) 0.78
Correlation between mean platelet volume and B-type natriuretic peptide concentration in emergency patients with heart failure. Biochem Med (Zagreb) (2015) 0.77
Usefulness of elevated urine neopterin levels in assessing cardiac dysfunction and exercise ventilation inefficiency in patients with chronic systolic heart failure. Am J Cardiol (2014) 0.76
Rehospitalizations among patients in the Medicare fee-for-service program. N Engl J Med (2009) 35.68
Heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation (2011) 31.98
The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation (2006) 6.58
Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med (1990) 5.65
The idiopathic hypereosinophilic syndrome. Blood (1994) 4.65
Association between performance measures and clinical outcomes for patients hospitalized with heart failure. JAMA (2007) 4.59
Trends in length of stay and short-term outcomes among Medicare patients hospitalized for heart failure, 1993-2006. JAMA (2010) 4.36
The eosinophilic leukocyte: structure and function. Adv Immunol (1986) 4.08
Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol (1996) 3.47
Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation (2004) 3.30
Prognostic significance of peripheral monocytosis after reperfused acute myocardial infarction:a possible role for left ventricular remodeling. J Am Coll Cardiol (2002) 3.27
Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation (2001) 3.15
Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Allergy Clin Immunol (2006) 3.04
Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet (1999) 3.01
Acute heart failure syndromes. J Am Coll Cardiol (2009) 2.91
Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation (1995) 2.91
Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation (2000) 2.18
Induction of functional inducible nitric oxide synthase in monocytes of patients with congestive heart failure. Link with tumour necrosis factor-alpha. Eur Heart J (1999) 2.12
Neutrophilia and congestive heart failure after acute myocardial infarction. Am Heart J (2000) 2.01
Deposits of eosinophil granule proteins in cardiac tissues of patients with eosinophilic endomyocardial disease. Lancet (1987) 1.98
Predictive power of the relative lymphocyte concentration in patients with advanced heart failure. Circulation (1998) 1.86
Monocyte chemoattractant protein-1. Chem Immunol (1999) 1.85
Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol (1998) 1.75
Does absolute neutrophilia predict early congestive heart failure after acute myocardial infarction? A cross-sectional study. South Med J (2008) 1.57
Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol (1999) 1.50
Elevated circulating levels of C-C chemokines in patients with congestive heart failure. Circulation (1998) 1.46
Utility of the neutrophil to lymphocyte ratio in predicting long-term outcomes in acute decompensated heart failure. Am J Cardiol (2011) 1.44
Immune activation in chronic heart failure. Am J Cardiol (2005) 1.37
The importance of the gastrointestinal system in the pathogenesis of heart failure. Eur Heart J (2005) 1.34
Incident heart failure hospitalization and subsequent mortality in chronic heart failure: a propensity-matched study. J Card Fail (2008) 1.32
Administration to mouse of endotoxin from gram-negative bacteria leads to activation and apoptosis of T lymphocytes. Eur J Immunol (1998) 1.23
The relative lymphocyte count on hospital admission is a risk factor for long-term mortality in patients with acute heart failure. Am J Emerg Med (2006) 1.21
Neutrophilia predicts death and heart failure after myocardial infarction: a community-based study. Circ Cardiovasc Qual Outcomes (2009) 1.16
Tumour necrosis factor-alpha and the failing heart--pathophysiology and therapeutic implications. Basic Res Cardiol (2003) 1.12
Load-dependent and -independent regulation of proinflammatory cytokine and cytokine receptor gene expression in the adult mammalian heart. Circulation (2002) 1.09
Role of interleukin-6 in cardiomyocyte/cardiac fibroblast interactions during myocyte hypertrophy and fibroblast proliferation. J Cell Physiol (2005) 1.08
Adrenergic control of circulating lymphocyte subpopulations. Effects of congestive heart failure, dynamic exercise, and terbutaline treatment. J Clin Invest (1990) 1.06
Cardiac mast cells: the centrepiece in adverse myocardial remodelling. Cardiovasc Res (2010) 1.06
A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial. Heart Fail Rev (2012) 1.05
Relative lymphocyte count: a prognostic indicator of mortality in elderly patients with congestive heart failure. Am Heart J (2001) 1.05
Endogenous cortisol: a regulator of the number of lymphocytes in peripheral blood. Clin Immunol Immunopathol (1980) 1.04
The role of monocytes and inflammation in the pathophysiology of heart failure. Eur J Heart Fail (2011) 1.03
The Th17/Treg imbalance exists in patients with heart failure with normal ejection fraction and heart failure with reduced ejection fraction. Clin Chim Acta (2010) 1.00
Invasive assessment of bacterial endotoxin and inflammatory cytokines in patients with acute heart failure. Eur J Heart Fail (2003) 0.95
White blood cell count, C-reactive protein, and incident heart failure in the Atherosclerosis Risk in Communities (ARIC) Study. Ann Epidemiol (2011) 0.93
Routine laboratory results and thirty day and one-year mortality risk following hospitalization with acute decompensated heart failure. PLoS One (2010) 0.93
CD14CD16 monocyte subset levels in heart failure patients. Dis Markers (2010) 0.93
Monocytes in heart failure: relationship to a deteriorating immune overreaction or a desperate attempt for tissue repair? Cardiovasc Res (2009) 0.93
White blood cell count and mortality in patients with ischemic and nonischemic left ventricular systolic dysfunction (an analysis of the Studies Of Left Ventricular Dysfunction [SOLVD]) Am J Cardiol (1999) 0.92
Low lymphocyte count and cardiovascular diseases. Curr Med Chem (2011) 0.90
The relative lymphocyte count predicts death in patients receiving implantable cardioverter defibrillators. Pacing Clin Electrophysiol (2002) 0.86
Usefulness of relative lymphocyte count as an independent predictor of death/urgent transplant in heart failure. Am J Cardiol (2005) 0.86
Intracellular monocyte cytokine production and CD 14 expression are up-regulated in severe vs mild chronic heart failure. J Heart Lung Transplant (2005) 0.84
Systemic inflammation and cell activation reflects morbidity in chronic heart failure. Cytokine (2011) 0.82
Differential white blood cell count and incident heart failure in men and women in the EPIC-Norfolk study. Eur Heart J (2011) 0.81
Hypoalbuminemia and lymphocytopenia in patients with decompensated biventricular failure. Am J Med Sci (2010) 0.81
Monocyte activation in congestive heart failure due to coronary artery disease and idiopathic dilated cardiomyopathy. Int J Cardiol (1998) 0.80
Clinical trials in acute heart failure: simpler solutions to complex problems. Consensus document arising from a European Society of Cardiology cardiovascular round-table think tank on acute heart failure, 12 May 2009. Eur J Heart Fail (2011) 0.79
Leukocyte redistribution: effects of beta blockers in patients with chronic heart failure. PLoS One (2009) 0.79
Reduced relative lymphocyte count in african-americans with decompensated heart failure. Am J Med Sci (2009) 0.78
Effectiveness of the relative lymphocyte count to predict one-year mortality in patients with acute heart failure. Am J Cardiol (2011) 0.78
Blood leukocytes in heart failure with preserved ejection fraction: impact on prognosis. Int J Cardiol (2012) 0.77
Cardiac mast cells: implications for heart failure. J Am Coll Cardiol (2007) 0.77
Absolute blood eosinophil count and 1-year mortality risk following hospitalization with acute heart failure. Eur J Emerg Med (2012) 0.77
Usefulness of total lymphocyte count as predictor of outcome in patients with chronic heart failure. Am J Cardiol (2011) 0.75
Usefulness of the percentage of plasma lymphocytes as a prognostic marker in patients with congestive heart failure. Jpn Heart J (2004) 0.75
Patterns of leukocyte counts on admissions for acute heart failure--presentation and outcome--results from a community based registry. Int J Cardiol (2009) 0.75
Low lymphocyte ratio as a novel prognostic factor in acute heart failure: results from the Pre-RELAX-AHF study. Cardiology (2010) 0.75
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J (2010) 16.39
Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation (2011) 14.00
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 11.88
Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med (2006) 10.63
A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest (2010) 10.29
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation (2013) 10.07
Apixaban in patients with atrial fibrillation. N Engl J Med (2011) 9.97
Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59
Third universal definition of myocardial infarction. Circulation (2012) 8.47
Third universal definition of myocardial infarction. Eur Heart J (2012) 7.98
Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med (2012) 6.60
Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J (2006) 6.31
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace (2010) 6.31
Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA (2007) 6.25
Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci (2002) 5.01
Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail (2013) 4.98
Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT₂R₂ score. Chest (2013) 4.71
Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med (2012) 4.69
Association between performance measures and clinical outcomes for patients hospitalized with heart failure. JAMA (2007) 4.59
Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J (2006) 4.55
Coronary computed tomography angiography for early triage of patients with acute chest pain: the ROMICAT (Rule Out Myocardial Infarction using Computer Assisted Tomography) trial. J Am Coll Cardiol (2009) 4.54
Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J (2005) 4.37
Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med (2010) 4.15
Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol (2004) 4.14
Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 4.01
Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol (2007) 3.92
2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation (2013) 3.86
Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. Lancet (2009) 3.83
Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J (2012) 3.66
The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J Am Coll Cardiol (2009) 3.55
Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol (2005) 3.53
Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation (2012) 3.47
Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure. Am J Med (2013) 3.46
Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation (2006) 3.40
Is atrial fibrillation an inflammatory disorder? Eur Heart J (2005) 3.33
Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction. JAMA (2008) 3.31
Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial. BMJ (2007) 3.30
Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA (2002) 3.24
Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol (2013) 3.13
Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol (2013) 3.06
Influence of a performance-improvement initiative on quality of care for patients hospitalized with heart failure: results of the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF). Arch Intern Med (2007) 2.95
Relation of nonsteroidal anti-inflammatory drugs to serious bleeding and thromboembolism risk in patients with atrial fibrillation receiving antithrombotic therapy: a nationwide cohort study. Ann Intern Med (2014) 2.91
Is hospital admission for heart failure really necessary?: the role of the emergency department and observation unit in preventing hospitalization and rehospitalization. J Am Coll Cardiol (2013) 2.89
Coronary multidetector computed tomography in the assessment of patients with acute chest pain. Circulation (2006) 2.82
The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol (2008) 2.79
Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF). Circulation (2010) 2.77
A smoker's paradox in patients hospitalized for heart failure: findings from OPTIMIZE-HF. Eur Heart J (2008) 2.71
Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF). Circ Heart Fail (2008) 2.69
Cardiac mitochondria in heart failure: decrease in respirasomes and oxidative phosphorylation. Cardiovasc Res (2008) 2.66
Mitral valve surgery in heart failure: insights from the Acorn Clinical Trial. J Thorac Cardiovasc Surg (2006) 2.62
The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J (2003) 2.57
Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current. J Cardiovasc Electrophysiol (2006) 2.56
Anxiety, depression, and prognosis after myocardial infarction: is there a causal association? J Am Coll Cardiol (2003) 2.54
Clinical benefits of low serum digoxin concentrations in heart failure. J Am Coll Cardiol (2002) 2.47
Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting. Am J Cardiol (2005) 2.47
The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail (2002) 2.45
Inflammatory markers and incident heart failure risk in older adults: the Health ABC (Health, Aging, and Body Composition) study. J Am Coll Cardiol (2010) 2.43
Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF. Arch Intern Med (2008) 2.42
New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. J Am Coll Cardiol (2012) 2.41
Chronic mechanical circulatory support for inotrope-dependent heart failure patients who are not transplant candidates: results of the INTrEPID Trial. J Am Coll Cardiol (2007) 2.41
RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. Eur Heart J (2011) 2.40
Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). J Am Coll Cardiol (2008) 2.39
Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. Am J Cardiol (2006) 2.37
Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. J Am Coll Cardiol (2008) 2.35
Incident heart failure prediction in the elderly: the health ABC heart failure score. Circ Heart Fail (2008) 2.33
Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design. Am Heart J (2004) 2.32
Role of microRNAs in cardiac remodelling: new insights and future perspectives. Int J Cardiol (2012) 2.32
Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thromb Haemost (2014) 2.29
The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea study. Eur Heart J (2009) 2.28
Virchow's triad revisited. South Med J (2004) 2.23
Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost (2011) 2.22
Bridging evidence-based practice and practice-based evidence in periprocedural anticoagulation. Circulation (2012) 2.20
Quality of life in patients with atrial fibrillation: a systematic review. Am J Med (2006) 2.17
Need for increased awareness and evidence-based therapies for patients hospitalized for heart failure. JAMA (2013) 2.17
Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J (2013) 2.17
Salt intake and Helicobacter pylori infection. J Hypertens (2004) 2.17
Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. J Am Coll Cardiol (2005) 2.16
Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation (2012) 2.16
Echocardiography, natriuretic peptides, and risk for incident heart failure in older adults: the Cardiovascular Health Study. JACC Cardiovasc Imaging (2012) 2.15
Endothelial progenitor cells in cardiovascular disorders. J Am Coll Cardiol (2007) 2.11
Ambulatory blood pressure monitoring in heart failure: a systematic review. Eur J Heart Fail (2005) 2.09
Association of major and minor ECG abnormalities with coronary heart disease events. JAMA (2012) 2.07
Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score? Circ Cardiovasc Interv (2012) 2.07
Indications for the use of diagnostic implantable and external ECG loop recorders. Europace (2009) 2.06
Prevalence of peripheral artery disease by abnormal ankle-brachial index in atrial fibrillation: implications for risk and therapy. J Am Coll Cardiol (2013) 2.05
Large-scale genomic studies reveal central role of ABO in sP-selectin and sICAM-1 levels. Hum Mol Genet (2010) 2.05